Zanubrutinib yielded sustained progression-free survival and a tolerable safety profile in older patients with CLL/SLL treated in the SEQUOIA trial.
Dissecting Long-Term Data for Zanubrutinib in Older Treatment-Naive CLL
Advertisement
Advertisement
Trending on OncLive
1
In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas
2
Subcutaneous Blinatumomab Yields High Efficacy Rates in R/R Ph+ B-ALL
3
Tacabrutideg Is Tolerable and Shows Efficacy Signals Across BTK Inhibitor–Naive CLL and Other B-Cell Malignancies
4
Rocbrutinib Shows Durable Efficacy in BTK Inhibitor–Pretreated R/R Mantle Cell Lymphoma
5